Drug Profile
H3B 6527
Alternative Names: H3B-6527Latest Information Update: 25 Apr 2022
Price :
$50
*
At a glance
- Originator H3 Biomedicine
- Developer Eisai Co Ltd; H3 Biomedicine
- Class Antineoplastics; Small molecules
- Mechanism of Action Type 4 fibroblast growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Liver cancer
- Discontinued Cholangiocarcinoma
Most Recent Events
- 25 Apr 2022 H3B 6527is still in phase I trials for Liver cancer (Late-stage disease, Second-line therapy or greater) in USA, Belgium, France, Italy and Spain (PO) (Eisai pipeline, April 2022)
- 28 Jan 2022 No recent reports of development identified for phase-I development in Liver-cancer(Late-stage disease, Second-line therapy or greater) in Belgium (PO)
- 28 Jan 2022 No recent reports of development identified for phase-I development in Liver-cancer(Late-stage disease, Second-line therapy or greater) in Canada (PO)